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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 201 Revision 1 
(FGE.201Rev1): 
2-Alkylated, aliphatic, acyclic alpha,beta-unsaturated aldehydes and precursors, 
with or without additional double-bonds, from chemical subgroup 1.1.2 of 
FGE.19.1 
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
 Processing Aids (CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider in this revision 1 of Flavouring Group Evaluation 201, the additional data on 
genotoxicity submitted by the Industry on two substances, 2-methylpent-2-enal [FL-no: 05.090] and 2 
methylcrotonaldehyde [FL-no: 05.095], from subgroup 1.1.2 of FGE.19. First the Panel concluded that genotoxicity 
data on [FL-no: 05.095] can be representative for the substances [FL-no: 02.174, 05.033, 05.090, 05.105, 05.107 and 
05.126], but not for [FL-no: 05.130, 05.178, 09.177 and 09.931], for which it was concluded in the previous version of 
this FGE that the available data were insufficient to evaluate their genotoxicity. Secondly, the Panel considers that 
the mutagenicity hazard could not be cleared by the endpoints evaluated in the in vivo micronucleus assay 
submitted. The Panel therefore concluded that further data are required in order to clarify the genotoxic 
potential of this subgroup. The Panel considers the Comet assay with [FL-no: 05.095] as test material and 
performed on liver, blood and first site of contact, as a preferred option to further investigate the genotoxicity 
in vivo. 
© European Food Safety Authority, 2012  
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in the 
Member States. In particular, the Panel was asked to evaluate flavouring substances using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000.  
In the present revision of FGE.201, FGE.201Rev1, there has been a reassessment of seven substances [FL-
no: 02.174, 05.033, 05.090, 05.095, 05.105, 05.107 and 05.126] from subgroup 1.1.2 of FGE.19, due to 
additional genotoxicity data submitted by Industry. 
The Flavouring Group Evaluation 201 (FGE.201), corresponding to subgroup 1.1.2 of FGE.19, concerns 
eight aliphatic acyclic 2-alkylated α,β-unsaturated aldehydes with or without additional double bonds [FL-
no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130 and 05.178] and three precursors for such 
aldehydes [FL-no: 02.174, 09.177 and 09.931]. 
In the previous version of this Opinion, FGE.201, the Panel had expressed the following view. 
No carcinogenicity studies are available for the eight α,β-unsaturated aldehydes and the α,β-unsaturated 
aldehydes anticipated to be formed from the precursors in subgroup 1.1.2. 
The genotoxicity concern with respect to this group of substances due to the presence of an α,β-unsaturated 
aldehyde group (or precursor for this) cannot be ruled out based on the genotoxicity data and (quantitative) 
structure-activity relationship (Q)SAR predictions available. 
Therefore, the Panel concluded that a genotoxic potential of the 11 α,β-unsaturated aldehydes and alcohols 
and related esters in the present FGE.201 could not be ruled out. Accordingly, these 11 substances cannot 
presently be evaluated through the Procedure. Additional data on genotoxicity on substances representative 
for this subgroup should be provided according to the Genotoxicity Test Strategy for Substances Belonging 
to Subgroups of FGE.19 (EFSA, 2008bb). 
 
In response to the Panel request expressed in FGE.201, the Flavouring Industry has submitted additional 
genotoxicity data.  
 
Based on these data the Panel concluded that there is some evidence for [FL-no: 05.095] and an indication 
for [FL-no: 05.090] to show a potency for the induction of gene mutations in vitro. Furthermore, the Panel 
considered that the mutagenicity hazard could not be cleared by the endpoints evaluated in the in vivo 
micronucleus assay and that further data are required in order to clarify the genotoxic potential of this 
subgroup. A Comet assay performed with [FL-no: 05.095] and performed on liver, blood and first site of 
contact was considered as a preferred option to further investigate the genotoxicity in vivo. Finally, the Panel 
concluded that the genotoxicity data for [FL-no: 05.095] could be representative for [FL-no: 02.174, 05.033, 
05.090, 05.105, 05.107 and 05.126] but not for the remaining substances of this subgroup [FL-no: 05.130, 
05.178, 09.177 and 09.931] for which it was already concluded in the previous version of this FGE that the 
available data were insufficient to evaluate their genotoxicity. 
JECFA EVALUATION:  
61st meeting: http://whqlibdoc.who.int/publications/2004/924166052X.pdf p289 
68th meeting: http://whqlibdoc.who.int/publications/2007/9789241209472_eng.pdf p59 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other flavouring substances in the EU. In application of that Regulation, a 
Register of flavouring substances used in or on foodstuffs in the Member States was adopted by 
Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 
2009/163/EC (EC, 2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) 
and all substances are divided into 34 chemical groups. Substances within a group should have some 
metabolic and biological behaviour in common.  
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union list of flavouring substances for use in or 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and/or oxidation (EFSA, 2008b). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into 28 subgroups on the basis of structural similarity 
(EFSA, 2008b). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the Procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. The Panel decided that 11 subgroups (1.1.2, 
1.1.3, 1.1.4, 2.4, 2.6, 2.7, 3.1, 3.3, 4.1, 4.2 and 4.4) (EFSA, 2008b) should be further examined to 
determine whether evaluation through the Procedure is feasible. Corresponding to these 11 subgroups, 
11 Flavouring Group Evaluations (FGEs) were established, FGE.201, 202, 203, 210, 212, 213, 214, 
216, 217, 218 and 220. If the Panel concludes for any substances in these 11 FGEs that they cannot be 
evaluated using the Procedure then it has to be decided if there is a safety concern for certain 
substances or if additional data are required in order to finalise the evaluation. If the Panel concludes 
that a genotoxic potential can be ruled out for the substances they will be merged with structurally 
related substances in other FGEs and evaluated using the Procedure. 
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HISTORY OF EVALUATION 
In FGE.201 the Panel concluded that additional genotoxicity data were required for all 11 α,β-
unsaturated aldehydes and alcohols and related esters considered in the FGE.  
 
In the EFSA Opinion “List of α,β-unsaturated aldehydes and ketones representative of FGE.19 
substances for genotoxicity testing” (EFSA, 2008bc), representative flavouring substances have been 
selected for subgroup 1.1.2, corresponding to FGE.201, for which additional data on genotoxicity 
were requested, according to the Opinion of the Panel on the ”Genotoxicity Test Strategy for 
Substances Belonging to Subgroups of FGE.19” (EFSA, 2008bb). 
Representative substances for subgroup 1.1.2 of FGE.19 (EFSA, 2008bc) 
FL-no  
JECFA-no  
EU Register name  Structural formula  Comments  
05.090 
1209 
2-Methylpent-2-enal  
 O
 
05.178  
1227  
 
beta-Sinensal  
 
O
 
 
Not in EU  
Register 
2-methyl-2-propenal  
or its  
precursor [09.177]  
 
O  
  
09.177 
1207 
2-Methylallyl butyrate O
O
 
 
The present FGE.201 Revision 1 (FGE.201Rev1) includes the assessment of additional genotoxicity 
data submitted by Industry in reply to a data request presented in FGE.201.  
Additional data has been provided by Industry (EFFA, 2011g) for the representative substance 2-
methylpent-2-enal [FL-no: 05.090] and a non-representative substance, also from subgroup 1.1.2, 2-
methylcrotonaldehyde [FL-no: 05.095]. No data has been submitted for the other representatives 
identified by EFSA (EFSA, 2008bc), beta-sinensal [FL-no: 05.178], 2-methyl-2-propenal [not a 
Register substance but a precursor for such] or its precursor 2-methylallyl butyrate [FL-no: 09.177]. 
According to Industry, [FL-no: 05.178 and 09.177] are not any longer supported by the Industry and 
accordingly no data were submitted for these substances due to the lack of test material for the 
required genotoxicity testing.  
The new data submitted for [FL-no: 05.090 and 05.095] are described and evaluated in Section 4 in 
the present FGE.201Rev1. Sections 1-3 report the same information that was present in the earlier 
version of FGE.201. 
FGE Adopted by 
EFSA 
Link No. of 
Substances 
FGE.201 25 September 
2008 
http://www.efsa.europa.eu/en/efsajournal/pub/1080.htm 11 
FGE.201Rev1   11 
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TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances prior to their authorisation and inclusion in a Union list according to Commission 
Regulation (EC) No 1565/2000 (EC, 2000a). 
In addition, in letter of 22 September 2011, the Commission requested EFSA to carry out a re-
evaluation on the nine substances 2-methylbut-2-en-1-ol [FL-no: 02.174], 2-ethylhept-2-enal [FL-no: 
05.033], 2-methylpent-2-enal [FL-no: 05.090], 2-methylcrotonaldehyde [FL-no: 05.095], 2-butylbut-
2-enal [FL-no: 05.105], 2-isopropyl-5-methylhex-2-enal [FL-no: 05.107],  2-methyloct-2-enal [FL-no: 
05.126], alpha-sinensal [FL-no: 05.130] and 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 
09.931], in accordance with Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
ASSESSMENT 
1. Presentation of the Substances in the Flavouring Group Evaluation 201, Revision 1 
1.1. Description 
The present Flavouring Group Evaluation 201, Revision 1 (FGE.201Rev1), concerns 11 substances, 
which are presented in Table 1. The 11 substances correspond to subgroup 1.1.2 of FGE.19 (EFSA, 
2008b). Eight of these substances are aliphatic acyclic 2-alkylated α,β-unsaturated aldehydes with or 
without additional double bonds [FL-no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130 and 
05.178] and three are precursors for such aldehydes [FL-no: 02.174, 09.177 and 09.931].  
A summary of their current evaluation status by the JECFA is given in Table 2 (JECFA, 2004b; 
JECFA, 2007c). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008b). Accordingly the available data on genotoxic or carcinogenic activity for the eight aldehydes in 
FGE.201 [FL-no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130 and 05.178] and the two 
aldehydes [non-Register substances, 2,6-dimethyl-2,5,7-octatrienal and 2-methyl-2-propenal, see 
Table 3] anticipated to be metabolism products formed from two of the three precursors in FGE.201 
[FL-no: 02.174, 09.177 and 09.931], will be considered in this FGE. The anticipated metabolism 
product formed from the third precursor [FL-no: 02.174] is one of the eight Register aldehydes in this 
FGE [FL-no: 05.095]. 
 
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR 
models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on the 10 aldehydes [FL-
no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130, 05.178, 2-methyl-2-propenal and 2,6-
dimethyl-2,5,7-octatrienal]. The 10 aldehydes and their (Q)SAR predictions are shown in Table 3. 
2. Toxicity 
2.1. (Q)SAR Predictions 
In Table 3 the outcomes of the (Q)SAR predictions for possible genotoxicity activity in five in vitro 
(Q)SAR models (ISS-Local Model-Ames Test, DTU-NFI-MultiCASE-Ames test, -Chromosomal 
aberration test in Chinese hamster ovary cells (CHO), -Chromosomal aberration test in Chinese 
hamster lung cells (CHL) and -Mouse Lymphoma Test) are presented. For the three short-chain 
aldehydes [FL-no: 05.095, 05.090 and 05.105] the predictions in the ISS Local Ames test (TA100) 
were positive. For 2-methyl-2-propenal, the DTU-NFI-MultiCASE Ames test was positive. All other 
predictions were either negative or out of domain (See Table 3). 
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2.2. Carcinogenicity Studies  
No carcinogenicity studies are available for the eight α,β-unsaturated aldehydes and the α,β-
unsaturated aldehydes anticipated to be formed from the three precursors [FL-no: 02.174, 09.177 and 
09.931] in subgroup 1.1.2. 
2.3. Genotoxicity Studies4 
Only one study on 2-methylpent-2-enal [FL-no: 05.090] and one study on 2-methyl-2-propenal [not in 
Register] is available for the eight aldehydes and the α,β-unsaturated aldehydes anticipated to be 
formed from the precursors in subgroup 1.1.2. The study on 2-methylpent-2-enal is a spot test (Florin 
et al., 1980), which is not in accordance with the OECD guideline. Furthermore, the methods and 
results are insufficiently reported and the study is considered to be of insufficient validity. The study 
on 2-methyl-2-propenal (and the structurally related 2-propyl and 2-butyl substituted 2-propenals), in 
Ames test in Salmonella typhimurium strain TA100, showed mutagenic effects of all the 2-alkylated 2-
propenals (Eder & Deininger, 2001). The study was found valid. See Table 5. 
2.4. Conclusion on Genotoxicity4 
The genotoxicity concern with respect to this group of substances due to the presence of an α,β-
unsaturated aldehyde group (or precursor for this) cannot be ruled out based on the genotoxicity data 
and (Q)SAR predictions available. 
3. Conclusion4 
The Panel concluded that a genotoxic potential of the 11 α,β-unsaturated aldehydes and alcohols and 
related esters in the present FGE.201 could not be ruled out. Accordingly the 11 substances cannot be 
evaluated through the Procedure. Additional data on genotoxicity on substances representative for this 
subgroup should be provided according to the Genotoxicity Test Strategy for Substances Belonging to 
Subgroups of FGE.19 (EFSA, 2008bb).  
4. Data submitted from Industry in reply to genotoxicity data requested in FGE.201 
4.1. In vitro assays 
4.1.1. Ames tests 
2-Methylpent-2-enal [FL-no: 05.090] was tested in S. typhimurium strains TA98, TA100, TA102, 
TA1535 and TA1537 in the presence and absence of metabolic activation by S-9 (Bowen, 2011). In 
the first experiment performed using plate incorporation methodology, concentrations of 1.6, 8, 40, 
200, 1000 and 5000 μg/plate were assessed for all tester strains. Evidence of toxicity was only 
observed in strains TA1537 at 5000 μg/plate in the presence of S-9 and TA102 at 1000 μg/plate and 
above in the presence of S-9. The concentration range was therefore narrowed for a second 
experiment. In addition, the second experiment included a supplementary S-9 pre-incubation step for 
the S-9 treatment group to increase the range of assay detection. Following these treatments, evidence 
of toxicity was observed in the presence of S-9 in S. typhimurium strains TA98, TA100, TA1535 and 
TA102 at 2500 μg/plate and above and in strain TA1537 at 1250 μg/plate and above. Toxicity was not 
observed in the absence of S-9. In the second experiment, at a single intermediate dose of 2500 
μg/plate without S-9 treatment in strain TA1537, there was a small (2.1-fold), statistically significant 
increase in revertants, but this was not dose-related and was within the range of historical controls. 
The Panel concluded that 2-methylpent-2-enal was not mutagenic in this study (Table 5 and 7b). 
                                                     
 
4 The conclusions in Section 2.3, 2.4 and Section 3 are cited from the first version of the present FGE, FGE.201. This 
conclusion is the basis for the request of additional genotoxicity data in FGE.201. 
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A bacterial reverse mutation assay was also conducted in S. typhimurium strains TA98, TA100, 
TA1535, TA1537, and Escherichia coli strain WP2uvrA with 2-methylcrotonaldehyde [FL-no: 
05.095] (Nakajima, 2006a), which does not belong to the substances selected as representative by the 
Panel for this subgroup. In an initial experiment the concentrations used were 8.19, 20.5, 51.2, 128, 
320, 800, 2000 and 5000 μg/plate. In strain TA100, 2-methylcrotonaldehyde increased the number of 
colonies showing reverse mutations, both with and without metabolic activation by S-9, in a dose-
dependent manner. In the absence of S-9, the increases were 3-fold from 320 - 5000 μg/plate and with 
S-9 metabolic activation the increases were up to 3.9-fold from 320 - 2000 μg/plate; under these 
conditions, growth inhibition was observed at 5000 μg/plate. In all other strains in the presence and 
absence of metabolic activation treatment with 2-methylcrotonaldehyde did not result in an increase of 
reverse mutant colony (Table 5 and 7a). 
In a second experiment using 2-methylcrotonaldehyde [FL-no: 05.095] concentrations of 156, 313, 
625, 1250, 2500 and 5000 μg/plate, treatment of strain TA100 in the absence of S-9 activation induced 
a dose-dependent increase in reverse mutant colonies (1.5 - 7.2 fold), with growth inhibition observed 
at 5000 μg/plate in the absence of S-9. In the presence of S-9, treatment of strain TA100 also gave a 
dose-dependent (313-2500 μg/plate) increase in reverse mutant colonies (1.2 - 4.6 fold), with growth 
inhibition again observed at 5000 μg/plate. In the absence of S-9, strain TA1535 gave a 1.8-fold 
increase in reverse mutants at 2500 μg/plate, but this was not dose-dependent. Strain TA98 had a 
nearly 2-fold increase in reverse mutant colonies in the absence of S-9 at both 2500 and 5000 μg/plate. 
These increases were above the historical control range but they were not clearly dose-related. In the 
presence of S-9, the same strain showed a 1.5-fold increase at 5000 μg/plate. E. coli strain WP2uvrA 
showed a 2-fold increase in reverse mutant colonies at 5000 μg/plate treatment without S-9 which was 
above the historical control range, but otherwise there was no increase at any other dose or with S-9 
treatment (Table 5 and 7a). 
Strain WP2uvrA did not show evidence of mutagenicity in the first experiment but produced weakly 
mutagenic results in the second experiment at the highest concentration tested. Since the repeatability 
of the result was not confirmed an additional experiment with this strain was performed from 156-
5000 μg/plate and this resulted in a 1.4-fold increase in revertant colonies at 2500 and 5000 μg/plate. 
The Panel considered these small increases as indication for a weak mutagenic potential because the 
effects were reproducible in two out of three experiments and were above the historical control range. 
However, with the exception of strain TA100, there were no increases in reverse mutation colonies 
exceeding that of the negative control by 2-fold. The Panel considered that 2-methylcrotonaldehyde 
[FL-no: 05.095] was mutagenic in the TA100 strain in the absence and presence of S-9 under the 
specified conditions of the assay. 
In order to clarify the ability of 2-methylcrotonaldehyde [FL-no: 05.095] to induce reverse mutations 
and provide cross-lab comparison of results, a third Ames assay was conducted (Ballantyne, 2011) in 
the same laboratory in which the Bowen 2011 study was performed. In order to directly compare 2-
methylcrotonaldehyde with 2-methylpent-2-enal, the latter was tested additionally in this assay. Both 
substances were tested in the single S. typhimurium strain TA100, in the absence and the presence of 
metabolic activation, in three separate experiments. 
The first experiment was conducted using final concentrations of 2-methylcrotonaldehyde [FL-no: 
05.095] and 2-methylpent-2-enal [FL-no: 05.090] at 1.6, 8, 40, 200, 1000 and 5000 μg/plate in strain 
TA100 with or without S-9. Following these treatments, no evidence of toxicity was observed. 
Statistically significant (p ≤ 0.01) increases in revertants were observed for 2-methylcrotonaldehyde at 
5000 μg/plate in the absence of S-9 metabolic activation (1.3-fold) and at all concentrations tested in 
the presence of S-9. In all cases, the increases were small versus concurrent controls (1.2–1.7 fold 
versus concurrent controls) but were above the range of historical controls. Similarly, for 2-
methylpent-2-enal, small statistically significant (p ≤ 0.05) increases in revertants (1.2-fold) were 
observed at 5000 μg/plate in the absence of S-9 metabolic activation and at 1.6, 200 and 5000 μg/plate 
(p ≤ 0.01) in the presence of S-9. In all cases, the increases were small versus concurrent controls 
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(1.2–1.4 fold versus concurrent controls) but the results obtained in the presence of S-9 were above the 
range of historical controls and dose-related (Table 5 and 7c). 
In the second experiment, treatment of strain TA100 with 2-methylcrotonaldehyde [FL-no: 05.095] 
and 2-methylpent-2-enal [FL-no: 05.090] was performed in the absence and in the presence of S-9 at 
narrowed concentration intervals. 2-Methylcrotonaldehyde and 2-methylpent-2-enal were assayed at 
51.2, 128, 320, 800, 2000 and 5000 μg/plate in the absence of S-9 using plate incorporation 
methodology and 8.192, 20.48, 51.2, 128, 320, 800, 2000 and 5000 μg/plate in the presence of S-9 
using both plate incorporation and pre-incubation methodology. Clear evidence of toxicity was only 
observed following pre-incubation methodology treatments with 2-methylcrotonaldehyde in the 
presence of S-9 at 5000 μg/plate and pre-incubation methodology treatments with 2-methylpent-2-enal 
in the presence of S-9 at 2000 and 5000 μg/plate. In the absence of S-9 activation, small but 
statistically significant increases in revertant colonies showing a dose-dependent relationship were 
observed for 2-methylcrotonaldehyde at 800, 2000 and 5000 μg/plate. These were only 1.3-1.4 fold 
over concurrent vehicle controls but above the range of historical controls. In the presence of S-9 
activation, 2-methylcrotonaldehyde showed a small but statistically significant increase in revertant 
colonies only at 5000 μg/plate using plate incorporation (1.4-fold) and at 800 and 2000 μg/plate using 
pre-incubation methodology (1.7-fold). These increases were above the historical control range. 
Similarly, in the presence of S-9 activation 2-methylpent-2-enal showed a small (1.4-fold) but 
statistically significant increase in revertants only at 5000 μg/plate using plate incorporation 
methodology, but in contrast gave no increases in revertant colonies using pre-incubation. In the 
absence of S-9 activation, a statistically significant increase in revertant colonies was observed at 5000 
μg/plate that was 2.5-fold over concurrent vehicle controls. These increases were above the historical 
control range, likewise (Table 5 and 7c). 
In order to further investigate the reproducibility and dose-relationship of some increases in revertant 
numbers seen in the first two experiments, a third experiment was performed with 2-
methylcrotonaldehyde [FL-no: 05.095] in the presence of S-9 (plate incorporation methodology only) 
and with 2-methylpent-2-enal in the absence of S-9. In order to investigate the dose range over which 
the increases in revertant numbers were previously observed, treatment concentration ranges of 0.32 - 
5000 μg/plate and 51.2 - 5000 μg/plate were employed for 2-methylcrotonaldehyde and 2-methylpent-
2-enal, respectively. Following these treatments, no evidence of toxicity was observed with both 
substances. For 2-methylcrotonaldehyde, small (1.3- to 1.8-fold) but statistically significant and dose-
related increases in revertants were observed at 1000 and 5000 μg/plate. These increases were above 
the historical control range. For 2-methylpent-2-enal, a small but statistically significant increase in 
revertants was observed at 5000 μg/plate. This increase was only 1.3-fold versus concurrent vehicle 
controls but above the historical control range.  
Overall, statistically significant increases in revertant numbers (when the data were analysed at the 1 
% level using Dunnett’s test) were observed in the absence and presence of S-9 in each experiment 
where the TA100 strain was treated with 2-methylcrotonaldehyde [FL-no: 05.095]. These increases 
provided evidence of a dose-relationship, with the exception of the first experiment in the absence of 
S-9, where the largest increase was observed at the lowest treatment concentration (1.6 μg/plate) and 
was attributed to an aberrant occurrence that was not reproduced in subsequent experiments. While the 
magnitude of these increases were small (1.3 - 1.8-fold above the concurrent control levels), these data 
were considered by the authors of the study report as evidence of 2-methylcrotonaldehyde mutagenic 
activity in strain TA100 in the absence and presence of metabolic activation with S-9. The Panel noted 
that these increases, although being small, was above the range of historical controls and that these 
effects were generally reproducible in the different experiments of this study. Thus, the Panel 
concluded that this study provided an indication for a weak mutagenic activity of 2-
methylcrotonaldehyde [FL-no: 05.095] in the presence and absence of metabolic activation. 
2-Methylpent-2-enal [FL-no: 05.090] treatments of strain TA100 in the absence and presence of S-9, 
assayed simultaneously for comparison to 2-methylcrotonaldehyde, resulted in statistically significant 
increases in revertant numbers in the absence and presence of S-9 in each experiment, with the 
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exception of experiment 2 using pre-incubation methodology in the presence of S-9. The maximum 
treatment concentration in the experiment 2 in the absence of S-9 resulted in a statistically significant 
increase of 2.5-fold over the concurrent control level, though this was not reproduced in experiments 1 
or 3, nor previously observed (Bowen, 2011). However, the small increases observed in experiments 1 
and 3 were statistically significant and above the range of historical controls. Thus, there is at least 
some consistency in these three experiments. The authors of the study report (Ballantyne, 2011) noted 
that all of the observed increases provided at least some evidence of dose dependence (in most cases 
the only responding concentration being the highest treatment concentration), and were reproducible 
over most of the treatment occasions. Accordingly, the authors considered that these increases are 
indicative of weak 2-methylpent-2-enal mutagenic activity in strain TA100 in the absence and in the 
presence of S-9 in this assay system. The Panel agreed with the authors. 
The details and conclusions for the Ames tests described above are summarised in Tables 5 and 7a to 
7d. 
4.1.2. In vitro Micronucleus assay 
2-Methylpent-2-enal [FL-no: 05.090] was evaluated in an in vitro micronucleus assay in human 
peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the 
presence and absence of rat liver metabolic activation system (S-9) as an in vitro metabolising system 
(Whitwell, 2011a). Cells were stimulated for 48 hours with phytohaemagglutinin to produce 
exponential cell growth followed by treatment for 3 hours (with a 21 hours recovery period) in the 
presence or absence of S-9 or 24 hours treatment with no recovery in the absence of S-9. In the first 
experiment, doses of 0, 100, 200 and 300 μg/ml of 2-methylpent-2-enal were tested. Frequencies of 
micronucleated binucleate (MNBN) cells were not significantly different (p ≤ 0.05) from that of the 
negative control in all conditions with the exception of the highest concentration analyzed post 3 + 21 
hours without S-9 treatment (300.0 μg/ml, inducing 49 % cytotoxicity, mean MNBN cells 1.05 %). 
This increase, although statistically significant relative to the concurrent vehicle control, was relatively 
small and did not exceed the range of historical controls (0.1 to 1.2 % MNBN cells). Furthermore, 
both replicate cultures at this concentration and all other 2-methylpent-2-enal concentrations analyzed 
were within a normal range of MNBN cell values.  
To clarify these data, a 3 + 21 hours treatment in the absence of S-9 was performed in a second 
experiment with 100.0, 175.0, 260.0 and 300.0 μg/ml concentrations of 2-methylpent-2-enal. 
Statistically significant increases in micronucleated cell frequencies were not observed. Consistent 
with current regulatory guideline recommendations for this assay, the maximum concentrations that 
were analyzed induced between 49 % to 57 % cytotoxicity. The Panel agreed with the authors of the 
study report and concluded that 2-methylpent-2-enal did not induce micronuclei in cultured human 
peripheral blood lymphocytes following treatment in the absence and presence of metabolic activation 
with S-9 (Table 5). 
 
4.1.3. In vitro chromosomal aberration assay 
The ability of 2-methylcrotonaldehyde [FL-no: 05.095] to induce chromosomal aberrations was 
evaluated in an in vitro assay using Chinese hamster pulmonic fibroblasts (Nakajima, 2006b). 
Microscopic observations were conducted during the chromosome aberration tests using short-term 
treatment with 3 or 4 different doses respectively, 105, 210 and 421 μg/ml in the absence of S-9 and 
105, 210, 421 and 841 μg/ml in the presence of S-9. The frequencies of chromosome structural 
aberrations as a result of short-term treatment of 2-methylcrotonaldehyde without metabolic activation 
by S-9 were 0.5 % in the negative control, 3.5 % in the 105 μg/mL treatment, 12.0 % in the 210 
μg/mL treatment, 55 % in the 421 μg/ml treatment and 50.0 % in the mitomycin positive control. The 
appearance of polyploidy cells was not observed at any dose and there were no significant reductions 
in relative cell growth rate under these test conditions. In the presence of S-9, the frequencies of 
chromosome structural aberration as a result of treatment using 2-methylcrotonaldehyde were 0.05 % 
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in the negative control, 1.5 % in the 105 μg/ml dose, 1.5 % in the 210 μg/ml dose, 33.0 % in the 421 
μg/ml dose, 96.5 % in the 841 μg/ml dose and 39 % in the cyclophosphamide positive control 
treatment group. The frequencies of appearance of polyploidy cells were equivalent to those of the 
negative control group at all doses and there was no significant reduction in relative cell growth rate. 
Therefore, a dose-dependent induction of structural chromosome aberrations was associated with 2-
methylcrotonaldehyde treatment in both short-term treatments with and without S-9 under testing 
conditions. An increase in numerical chromosomal aberrations was not observed. The Panel agreed 
with the authors of the study report and concluded that 2-methylcrotonaldehyde induced chromosomal 
aberrations in cultured mammalian cells in the presence and absence of metabolic activation (Table 5). 
4.2. In vivo genotoxicity tests 
4.2.1. Micronucleus assay 
2-Methylcrotonaldehyde [FL-no: 05.095] was tested in an in vivo micronucleus assay using BDF1 
male mice (Nakajima, 2007). Five mice per group were administered by oral gavage with a dose of 2-
methylcrotonaldehyde once per day for two consecutive days at either 250, 500 or 1000 mg/kg bw 
(1000 mg/kg bw was the maximum tolerable dose based on an initial dose-finding study in which two 
out of three animals died after administration of 2000 mg/kg bw). The bone marrow cells were 
sampled 24 hours after the second dosing. Administration of 2-methylcrotonaldehyde resulted in one 
case of pilo-erection 25 hours after the first administration of 1000 mg/kg. No other treatment groups 
showed any sign of toxicity by means of visual examination or by body weight loss. There was no 
statistically significant increase in the frequency of micronucleated erythrocytes in treated groups 
compared to the negative control group. The ratio of polychromatic erythrocytes among total 
erythrocytes was not changed. Thus, the exposure of the bone marrow to the test substance could not 
be demonstrated based on that parameter. However, since mortality was observed at a dose of 2000 
mg/kg bw in the dose-finding study the Panel considered that systemic availability of the test 
substance could be assumed at the highest dose of 1000 mg/kg bw in the micronucleus assay. 
Although, it may be assumed that the bone marrow was exposed to the test substance since the bone 
marrow is a well perfused tissue, no conviencing evidence was provided. The Panel considered the 
study to be compliant with OECD guideline 474 except that no justification for the use of a single sex 
was given in the report, i.e. no data demonstrating that there are no substantial differences between 
sexes in toxicity. It was concluded that 2-methylcrotonaldehyde did not induce micronuclei in mice 
bone-marrow cells (Table 6). 
5. Discussion of the additional data 
2-Methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095] were tested in a 
series of in vitro tests to explore their genotoxicity potential.  
For 2-methylcrotonaldehyde [FL-no: 05.095], there is some evidence for a mutagenic activity in the 
presence and absence of metabolic activation. This is based on two reliable studies on the induction of 
bacterial gene mutations (Nakajima, 2006a; Ballantyne, 2011) with the first study providing clear 
evidence for mutagenic activity and the latter study providing indication for a weak mutagenic 
activity. 
For the representative substance 2-methylpent-2-enal [FL-no: 05.090] there is an indication for a weak 
mutagenic activity both in the presence and absence of metabolic activation. This indication is based 
on the results of one reliable study (Ballantyne, 2011) and structural similarity with 2-
methylcrotonaldehyde [FL-no: 05.095]. 
In vitro assessment of micronucleus induction by 2-methylpent-2-enal in the presence and absence of 
S-9 metabolic activation was negative. In the case of 2-methylcrotonaldehyde a dose-dependent 
induction of structural, but not numerical chromosomal aberrations in vitro was observed, both with 
and without S-9. To further investigate the clastogenic potential an in vivo micronucleus assay using 
BDF1 male mice was performed and no evidence of clastogenic effects was identified but the 
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respective test was inconclusive. These data support absence of clastogenicity for the two substances 
2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095].  
However, since there is some evidence for 2-methylcrotonaldehyde [FL-no: 05.095] and an indication 
for 2-methylpent-2-enal [FL-no: 05.090] to show a potency for the induction of gene mutations in 
vitro the Panel considered the mutagenicity hazard not cleared by the endpoints evaluated in the in 
vivo micronucleus assay. The Panel therefore concluded that further data are required in order to 
clarify the genotoxic potential of this subgroup. The Panel considers the in vivo Comet assay as a 
preferred option to further investigate the genotoxicity in vivo. The Comet assay will also be 
accountable to explore any genotoxicity at the first site of contact where higher concentrations of the 
test substance are expected to occur. In this view the in vivo Comet assay should be performed on 
liver, blood and first site of contact (e.g. duodenum or stomach). Alternatively, a transgenic rodent 
gene mutation assay (OECD TG 488) in tissues including first site of contact would also be 
acceptable.  
Since 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095] are closely 
related chemical structures, it is expected that they will have a similar reactivity behaviour. Since the 
evidence for a mutagenic activity in vitro is stronger for 2-methylcrotonaldehyde [FL-no: 05.095] than 
for 2-methylpent-2-enal [FL-no: 05.090] the Panel considers that additional data for the former 
substance are required. A negative result of 2-methylcrotonaldehyde [FL-no: 05.095] in the in vivo 
assay would be considered representative for the following substances of this subgroup [FL-no: 
02.174, 05.033, 05.090, 05.105, 05.107 and 05.126]. A positive result of 2-methylcrotonaldehyde (FL-
no: 05.095) in the in vivo assay will require further testing of these six substances [FL-no: 02.174, 
05.033, 05.090, 05.105, 05.107 and 05.126] in order to finalise their evaluation. 
The Panel noted that the Industry has communicated that the following two substances [FL-no: 05.178 
and 09.177] are not supported any more. These two substances were selected as representative for the 
substances in subgroup 1.1.2 and in addition also for substances in subgroup 2.1 (FGE.207). Since no 
data will be provided for these substances, they cannot further be used as representatives for the 
substances [FL-no: 02.122, 09.034, 09.712, 09.809] in FGE.207.  
 
2-Methylpent-2-enal (FL-no: 05.090) was originally selected as representative for the subgroup 1.1.2 
and also for the substances in subgroup 5.3 (FGE.225). Since the Panel now considers that additional 
data are required for 2-methylcrotonaldehyde these data could also be considered representative for 
the substances in FGE.225 [FL-no: 12.065, 12.079]. 
The genotoxicity studies are summarized in Tables 5, 6 and 7a to 7d. 
6. Conclusion 
Since there is some evidence for 2-methylcrotonaldehyde [FL-no: 05.095] and an indication for 2-
methylpent-2-enal [FL-no: 05.090] to show a potency for the induction of gene mutations in vitro the 
Panel considered the mutagenicity hazard not cleared by the endpoints evaluated in the in vivo 
micronucleus assay on 2-methylcrotonaldehyde [FL-no: 05.095]. The Panel therefore concluded that 
further data are required in order to clarify the genotoxic potential of this subgroup. The Panel 
considers the in vivo Comet assay as a preferred option to further investigate the genotoxicity in vivo. 
Since the evidence for a mutagenic activity in vitro is stronger for 2-methylcrotonaldehyde [FL-no: 
05.095] than for 2-methylpent-2-enal [FL-no: 05.090] the Panel considers that additional data for 2-
methylcrotonaldehyde are required. The Panel concluded that the genotoxicity data for 2-
methylcrotonaldehyde cannot be considered representative for the remaining substances of this 
subgroup [FL-no: 05.130, 05.178, 09.177 and 09.931] for which it was already concluded in the 
previous version of this FGE that the available data were insufficient to evaluate their genotoxicity.  
 
The Panel noted that this conclusion will also have consequences for the read across for substances in 
subgroups 2.1 and 5.3 (FGE.207 and FGE.225). 
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TABLE 1  SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FGE.201REV1 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 201, Revison 1 (JECFA, 2003b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.174 
1617 
2-Methylbut-2-en-1-ol OH
 
 
10258 
4675-87-0 
Liquid 
C5H10O 
86.13 
 
Freely soluble 
137 
 
 
95 % 
1.439-1.445 
0.863-0.869 
05.033 
1216 
2-Ethylhept-2-enal 
O
 
2438 
120 
10031-88-6 
Liquid 
C9H16O 
140.23 
Insoluble 
Soluble 
55-60 (5 hPa) 
 
NMR 
97 % 
1.460-1.466 
0.891-0.898 
05.090 
1209 
2-Methylpent-2-enal 
O
 
3194 
2129 
623-36-9 
Liquid 
C6H10O 
98.15 
Insoluble 
Soluble 
137 
 
IR MS 
92 % 
1.445-1.453 
0.855-0.865 
05.095 
1201 
2-Methylcrotonaldehyde 
O  
3407 
2281 
497-03-0 
Liquid 
C5H8O 
84.12 
Slightly soluble 
Soluble 
117-118 
 
IR NMR 
99 % 
1.445-1.450 
0.868-0.873 (20°) 
05.105 
1214 
2-Butylbut-2-enal O
 
3392 
10324 
25409-08-9 
Liquid 
C8H14O 
126.20 
Insoluble 
Soluble 
50 (18 hPa) 
 
NMR 
97 % 
1.447-1.453 
1.449-1.459 (20°) 
05.107 
1215 
2-Isopropyl-5-methylhex-2-enal 
O
3406 
10361 
35158-25-9 
Liquid 
C10H18O 
154.25 
Insoluble 
Soluble 
189 
 
NMR 
95 % 
1.448-1.454 
0.840-0.846 
05.126 
1217 
2-Methyloct-2-enal 
O
 
3711 
10363 
49576-57-0 
Liquid 
C9H16O 
140.23 
Insoluble 
Soluble 
70-75 (10 hPa) 
 
IR 
96 % 
1.449-1.459 
0.872-0.882 
05.130 
 
alpha-Sinensal O
 
3141 
10380 
17909-77-2 
 
 
218.34 
 
 
 
 
 
 
 
 
05.178 
1227 
beta-Sinensal O
 
3141 
10381 
60066-88-8 
Liquid 
C15H22O 
218.34 
Insoluble 
Soluble 
180 (1 hPa) 
 
NMR 
99 % 
1.504-1.513 
0.917-0.923 
09.177 
1207 
2-Methylallyl butyrate O
O
 
2678 
572 
7149-29-3 
Liquid 
C8H14O2 
142.20 
Insoluble 
Soluble 
168 
 
NMR 
97 % 
1.422-1.428 
0.873-0.883 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 201, Revison 1 (JECFA, 2003b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
09.931 
1226 
2,6-Dimethyl-2,5,7-octatriene-1-ol 
acetate 
O
O
 
3886 
 
999999-91-4 
Liquid 
C12H18O2 
194.28 
Insoluble 
Soluble 
70 (3 hPa) 
 
IR NMR MS 
96 % 
1.490-1.500 
0.937-0.947 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2 SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE  
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (JECFA, 2004b; JECFA, 2007c) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
EU 
USA 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
EFSA conclusion 
02.174 
1617 
2-Methylbut-2-en-1-ol OH
 
0.037 
 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.033 
1216 
2-Ethylhept-2-enal 
O
 
0.012 
0.1 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.090 
1209 
2-Methylpent-2-enal 
O
 
3.4 
0.2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.095 
1201 
2-Methylcrotonaldehyde 
O  
0.61 
0.2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.105 
1214 
2-Butylbut-2-enal O 0.0 
0.01 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.107 
1215 
2-Isopropyl-5-methylhex-2-enal 
O
0.24 
0.01 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.126 
1217 
2-Methyloct-2-enal 
O
 
0.0 
7.9 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201Rev1, additional in vivo 
genotoxicity data required 
05.178 
1227 
beta-Sinensal O
 
0.91 
0.5 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201, additional genotoxicity data 
required 
09.177 
1207 
2-Methylallyl butyrate O
O
ND 
0.2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201, additional genotoxicity data 
required 
09.931 
1226 
2,6-Dimethyl-2,5,7-octatriene-1-ol 
acetate 
O
O
1.2 
7.7 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.201, additional genotoxicity data 
required 
05.130 
 
alpha-Sinensal O
 
 
 
Not evaluated by JECFA  Evaluated in FGE.201, additional genotoxicity data 
required 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day , Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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TABLE 3 (Q)SAR PREDICTIONS ON MUTAGENICITY FOR NINE ALDEHYDES REPRESENTING THE SUBSTANCES IN SUBGROUP 1.1.2 
Table 3: (Q)SAR Predictions on Mutagenicity in Five Models for nine aldehydes Representing the Substances in Subgroup 1.1.2 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
ISS Local Model 
Ames Test TA100 
 
MultiCASE  
Ames test 
  
MultiCASE 
Mouse lymphoma 
test 
MultiCASE 
Chromosmal 
aberration test in 
CHO 
MultiCASE 
Chromosmal 
aberration test in 
CHL 
05.095 
1201 
2-Methylcrotonaldehyde 
O  
3407 
2281 
497-03-0 
POS NEG OD OD NEG 
05.090 
1209 
2-Methylpent-2-enal 
O
 
3194 
2129 
623-36-9 
POS NEG OD NEG NEG 
05.105 
1214 
2-Butylbut-2-enal O
 
3392 
10324 
25409-08-9 
POS NEG OD OD NEG 
05.107 
1215 
2-Isopropyl-5-methylhex-2-enal 
O
3406 
10361 
35158-25-9 
NEG NEG OD OD OD 
05.033 
1216 
2-Ethylhept-2-enal 
O
 
2438 
120 
10031-88-6 
NEG NEG OD OD NEG 
05.126 
1217 
2-Methyloct-2-enal 
O
 
3711 
10363 
49576-57-0 
NEG NEG NEG NEG NEG 
05.130 
 
alpha-Sinensal O
 
3141 
10380 
17909-77-2 
NEG NEG OD NEG NEG 
05.178 
1227 
beta-Sinensal O
 
3141 
10381 
60066-88-8 
NEG NEG OD NEG NEG 
Not in Register 2-methyl-2-propenal 
 
O  
- 
- 
78-85-3 
NYA POS OD OD OD 
Not in Register 2,6-dimethyl-2,5,7-octatrienal 
O
 
- 
- 
- 
NYA NEG OD NEG NEG 
Column 2: Structure group 1.1.2: Aliphatic acyclic α,β-unsaturated 2-alkylated aldehydes.  
Column 6: Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD: out of domain; NYA: not yet assessed). 
Column 7: MultiCase Ames test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 8: MultiCase Mouse Lymphona test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 9: MultiCase Chromosomal aberration in CHO (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 10: MultiCase Chromosomal aberration in CHL (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, biological, etc. 
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TABLE 4 CARCINOGENICITY STUDIES 
No carcinogenicity studies are available for the aldehydes and the aldehydes anticipated to be formed from the precursors in subgroup 1.1.2. 
TABLE 5 GENOTOXICITY (IN VITRO) 
In vitro studies available for the group of aldehydes and the aldehydes anticipated to be formed from the precursors in subgroup 1.1.2. 
 
Table 5: Genotoxicity (in vitro) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported Result  Reference  Comments b) 
2-Methylpent-2-enal  
[05.090] 
Reverse mutation S. typhimurium TA98, TA100 0.03–3mmol/plate 
(2.94–294mg/plate) 
Negativea (Florin et al., 1980) Insufficient validity (spot test, not according to 
OECD guideline, methods and results 
insufficiently reported). 
S. typhimurium TA98, TA100, TA102, 
TA1535 and TA1537 
1.6, 8, 40, 200, 1000 and 5000 
μg/plate 
Negativea,c (Bowen, 2011) d Valid. The study was performed in 
compliance with GLP and according to OECD 
TG 471. 
78.13, 156.13, 312.5, 625, 1250, 
2500 and 5000 μg/plate 
Negativea,h f
S. typhimurium TA100 
 
1.6, 8, 40, 200, 1000 and 5000 μg 
/plate 
Negative (-S9, Plate)a,,c
Weakly positive (+S9, 
Plate) 
(Ballantyne, 2011) 
 
g Valid. The study was performed in 
compliance with GLP and according to OECD 
TG 471 except that only one bacterial strain 
was used.   51.2, 128, 320, 800, 2000 and 
5000 μg/plate 
Weakly positive (-S9, 
Plate)c,e 
8.192, 20.48, 51.2, 128, 320, 800, 
2000 and 5000 μg/plate 
Weakly positive (+S9, 
Plate) 
Negative (+S9, Pre-
inc)c, h, i 
51.2, 128, 320, 800, 2000 and 
5000 μg/plate 
Weakly positive (-S9, 
Plate)c,e 
Micronucleus induction Human peripheral blood lymphocytes 100, 200 and 300 μg/ml Negativee,j (Whitwell, 2011a) k Valid. The study was performed in 
compliance with GLP and according to OECD 
TG 487. 
200, 275 and 350 μg/ml Negativei,j
20, 50, 70 and 80 μg/ml 
100, 175, 260 and 300  
Negativee,l
Negativec, j 
 
 
2-methylacrolein 
2-Methyl-2-propenal 
Ames test S. typhimurium  TA100 0-2 micromol/plate (- S9) 
0-9 micromol/plate (+ S9) 
 
Positivea (Eder and Deininger, 
2001) 
Valid. Positive both with and without S9-mix. 
Toxic at 1 micromol/plate and above (- S9) and 
6 micromol/plate (+ S9) evident as a reduction 
in revertants. 
2-Methylcrotonaldehyde 
[05.095] 
Reverse mutation S. typhimurium TA98, TA100, TA1535, 
TA1537, and Escherichia coli WP2uvrA 
8.19, 20.5, 51.2, 128, 320, 800, 
2000 and 5000 μg/plate 
Positivea,c (TA100) (Nakajima, 2006a) m  Valid. According to the study report, the 
study was performed in compliance with 
Japanese GLP standards. The study report 
contained a certificate of reliability but no 
details of inspection. The study is in 
accordance with OECD except that only two 
156, 313, 625, 1250, 2500 and 
5000 μg/plate 
Positivea,c (TA100) 
Weakly positive 
(WP2uvrA, -S9) 
E. coli WP2uvrA 156, 313, 625, 1250, 2500 and Negativea,
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Table 5: Genotoxicity (in vitro) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported Result  Reference  Comments b) 
5000 μg/plate plates were used per concentration. No 
statistics were performed. 
S. typhimurium TA100 1.6, 8, 40, 200, 1000 5000 
μg/plate 
Weakly positive (+/- 
S9, Plate)a,c 
(Ballantyne, 2011) n  Valid. The study was performed in 
compliance with GLP and according to OECD 
TG 471 except that only one bacterial strain 
was used. 
51.2, 128, 320, 800, 2000 and 
5000 μg/plate 
Weakly positive (+/- 
S9, Plate)a,c 
8.192, 20.48, 51.2, 128, 320, 800, 
2000 and 5000 μg/plate 
Weakly positive (+S9, 
Pre)h,i 
0.32, 1.6, 8, 40, 200, 1000 and 
5000 μg/plate 
Weakly positive (+S9, 
Plate)c,i 
Chromosomal aberration Chinese hamster Pulmonic fibroblasts 105, 210 and 421 μg/mL without 
S-9 treatment and 105, 210, 421 
and 841 μg/mL with S-9 
treatment 
Positive (Nakajima, 2006b) o Valid. According to the study report, the 
study was performed in compliance with 
Japanese GLP standards. The study report 
contained a certificate of reliability but no 
details of inspection. Mainly in accordance 
with OECD TG 473. 
a With and without metabolic activation. 
b Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
c Plate incorporation method. 
d Toxicity was observed in TA1537 at 5000 μg/plate in the presence of S-9 and in TA102 at 1000 μg/plate and above in the presence of S-9. 
e Without S9 metabolic activation. 
f Toxicity was observed in all strains in the presence of S-9 above 2500 μg/plate and 1250 μg/plate in TA1537. Study design complied with current recommendations. Acceptable top concentrations were achieved. 
g Throughout experiments some small but statistically significant increases were seen but these were attributed to normal biological variability, and were generally less than 2-fold over concurrent vehicle controls. 
h Pre-incubation method. 
i With S9 metabolic activation. 
j 3-hours incubation with 21-hours recovery period. 
k Complies with draft OECD guideline 487. Acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the study. 
l 24-hours incubation with no recovery period. 
m Study design complied with curent recommendations. Acceptable top concentrations were achieved. 
n Throughout experiments some small but statistically significant increases were  generally less than 2-fold over concurrent vehicle controls. 
o Dose dependent increase in induction of structural chrosomal abberations with and without S-9 treatment. No changes in numerical chromosomal aberrations were observed. 
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TABLE 6 GENOTOXICITY (IN VIVO) 
One in vivo study is available for the group of aldehydes and the aldehydes anticipated to be formed from the precursors in subgroup 1.1.2. 
Table 6: Genotoxicity (in vivo) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments b) 
Trans-2-methyl-2-butenal 
[05.095] 
In vivo Micronucleus 
induction 
BDF1 male mice 250, 500 and 1000 mg/kg 
bw per day by oral gavage 
Negative (Nakajima, 2007) Valid. According to the study report, the 
study was performed in compliance with 
Japanese GLP standards. The study report 
contained a certificate of reliability but no 
details of inspection. The Panel considered 
the study to be compliant with OECD 
guideline 474 except that no justification for 
the use of a single sex was given in the 
report, i.e. no data demonstrating that there 
are no substantial differences between sexes 
in toxicity. 
b Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
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TABLE 7A AMES-TEST WITH 2-METHYL-2-BUTENAL [05.095] (NAKAJIMA, 2006A) 
Non-toxic effects 
Table 7a: Ames-Test with 2-Methyl-2-butenal [05.095] (Nakajima, 2006a) 
 S9 Assay TA 98 TA 100 TA 1535 TA 1537 WP2uvrA Comment Conclusion 
Range-finding Experiment - Pre 1.4-fold 
< HC 
d-r 
 3-fold 
> HC 
d-r 
2.0-fold 
< HC 
not d-r 
1.6-fold 
< HC 
not d-r 
1.2-fold 
< HC 
(d-r) 
 Positive in TA 100 
+ Pre 1.2-fold 
< HC 
(d-r) 
3.9-fold 
> HC 
d-r 
1.4-fold 
< HC 
not d-r 
1.0-fold 
< HC 
 
1.3-fold 
< HC 
(d-r) 
 Positive in TA 100 
Experiment 1 - Pre 2.0-fold 
> HC 
not d-r 
7.2-fold 
> HC 
d-r 
1.8-fold 
< HC 
not d-r 
1.9-fold 
< HC 
(d-r) 
2.1-fold 
> HC 
(d-r) 
WP2uvrA-result not 
clearly reproducible 
Positive in TA 100,  
equivocal in WP2uvrA 
+ Pre 1.5-fold 
< HC 
(d-r) 
4.6-fold 
> HC 
d-r 
1.5-fold 
< HC 
not d-r 
1.0-fold 
< HC 
 
1.2-fold 
< HC 
not d-r 
 Positive in TA 100 
Experiment 2 - Pre     1.4-fold 
> HC 
(d-r) 
 Equivocal 
+ Pre 
 
       
Two plates were used per concentration. No examinations using statistical procedures were conducted. 
> HC, above historical control; < HC, within historical control. 
d-r, dose-related; (d-r), not clearly dose-related but the highest dose resulted in the largest increase, not d-r, not dose-related. 
Pre, Pre-incubation assay 
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TABLE 7B AMES-TEST WITH 2-METHYLPENT-2-ENAL [05.090] (BOWEN, 2011) 
Statistically significant increases, non-toxic effects 
Table 7b: Ames-Test with 2-Methylpent-2-enal [05.090] (Bowen, 2011) 
 S9 Assay TA 98 TA 100 TA 1535 TA 1537 TA 102 Comment Conclusion 
Range-finding Experiment - Plate  1.2-fold 
< HC 
d-r 
    Negative 
+ Plate  1.2-fold 
< HC 
not d-r 
    Negative 
Experiment 1 - Plate 
 
NS NS NS NS NS  Negative 
+ Plate NS 1.2-fold 
< HC 
not d-r 
NS NS NS  Negative 
Experiment 2 - Pre NS 1.2-fold 
< HC 
not d-r 
NS 2.1-fold 
< HC 
not d-r 
NS  Negative 
+ Pre NS NS NS 1.6-fold 
< HC 
not d-r 
NS  Negative 
> HC, above historical control; < HC, within historical control. 
NS, statistically not significant. 
d-r, dose-related but only the highest dose statistically significant; D-R, dose-related and at least two doses statistically significant. 
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TABLE 7C AMES-TEST WITH TA 100 (BALLANTYNE, 2011)  
Statistically significant increases not accompanied by toxicity 
Table 7c: Ames-Test with TA 100 (Ballantyne, 2011) 
Register name 
[FL-no] 
S9 Assay Exp 1 Exp 2 Exp 3 Comment Conclusion 
2-Methylcrotonaldehyde  
[05.095] 
- Plate 1.3-fold 
> HC 
Not d-r 
1.4-fold 
> HC 
d-r 
 Reproducible Indication for a weak mutagenic activity 
+ Plate 1.7-fold 
> HC 
d-r 
1.4-fold 
> HC 
d-r 
1.8-fold 
> HC 
d-r 
Reproducible  Indication for a weak mutagenic activity 
- Pre 
 
     
+ Pre  1.7-fold 
> HC 
d-r 
 Reproducible when compared with 
the plate-incorporation experiment 
Indication for a weak mutagenic activity 
2-Methylpent-2-enal 
[05.090] 
- Plate 1.2-fold 
< HC 
d-r 
2.5-fold 
> HC 
d-r 
1.3-fold 
> HC 
d-r 
Reproducible Indication for a weak mutagenic activity 
+ Plate 1.4-fold 
> HC 
d-r 
1.4-fold 
> HC 
d-r 
 Reproducible Indication for a weak mutagenic activity 
- Pre 
 
     
+ Pre  NS 
< HC 
   
> HC, above historical control; < HC, within historical control. 
NS, statistically not significant. 
d-r, dose-related but only the highest dose statistically significant; D-R, dose-related and at least two doses statistically significant. 
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TABLE 7D AMES-TEST RESULTS FOR 2-METHYLCROTONALDEHYDE [05.095] AND 2-METHYLPENT-2-ENAL [05.090] 
 
Table 7d: Ames-Test results for 2-methylcrotonaldehyde [05.095] and 2-methylpent-2-enal [05.090] 
Register name 
[FL-no] 
S9 Nakajima
(2006) 
Bowen 
(2011) 
Ballantyne 
(2011) 
Comment Conclusion 
2-Methylcrotonaldehyde  
[05.095] 
- Positive  Indication for a weak 
mutagenic activity 
At least the indication is reproducible. Indication for a mutagenic activity based on two studies. 
+ Positive  Indication for a weak 
mutagenic activity 
At least the indication is reproducible. Indication for a mutagenic activity based on two studies. 
2-Methylpent-2-enal 
[05.090] 
-  Negative Indication for a weak 
mutagenic activity 
The indication was not reproducible in 
different studies. Inconsistent results. 
Indication for a weak mutagenic activity based on the results of 
one study and structural similarity with 2-methylcrotonaldehyde 
[05.095]. 
+  Negative Indication for a weak 
mutagenic activity 
The indication was not reproducible in 
different studies. Inconsistent results. 
Indication for a weak mutagenic activity based on the results of 
one study and structural similarity with 2-methylcrotonaldehyde 
[05.095]. 
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 ABBREVIATIONS 
BW  Body weight 
CAS  Chemical Abstract Service 
CHL  Chinese hamster lung cell(s) 
CHO  Chinese hamster ovary cell(s) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DTU-NFI Danish Technical University – National Food Institute 
EC  European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS Flavour Information System database 
ID  Identity 
IR  Infrared spectroscopy 
ISS  Istituto Superiore di Sanita 
JECFA The Joint FAO/WHO Expert Committee on Food Additives 
MS  Mass spectrometry 
MSDI  Maximum Survey-derived Daily Intake 
NMR  Nuclear magnetic resonance 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Programme 
OECD  Organisation for Economic Co-operation and Development 
PCE/NCE Polychromatic erythrocytes/normochromatic erythrocytes 
(Q)SAR (Quantitative) structure-activity relationship 
SCE  Sister chromatid exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA synthesis 
US EPA United States Environmental Protection Agency 
WHO  World Health Organisation 
 
